Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
Miguel Muñoz, Rafael Coveñas
Cancers (2020) Vol. 12, Iss. 9, pp. 2682-2682
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

The anti-tumoral role of Hesperidin and Aprepitant on prostate cancer cells through redox modifications
Sanaz Akbari, Reza Assaran Darban, Hossein Javid, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 12, pp. 3559-3567
Closed Access | Times Cited: 25
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy
Smita Kumari, Rohan Gupta, Rashmi K. Ambasta, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188913-188913
Closed Access | Times Cited: 24
Synergistic Anticancer Effects of Liposomal Doxorubicin and Aprepitant Combination Therapy in Breast Cancer: Preclinical Insights and Therapeutic Potential
Atefeh Ghahremanloo, Fereshteh Asgharzadeh, Fatemeh Gheybi, et al.
Journal of Drug Delivery Science and Technology (2025), pp. 106620-106620
Closed Access | Times Cited: 1
Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain
Yang Yang, Wei Zhou, Xiuqi Xu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 33
SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant
Safieh Ebrahimi, Farshad Mirzavi, Seyed Hamid Aghaee‐Bakhtiari, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022) Vol. 1869, Iss. 5, pp. 119221-119221
Open Access | Times Cited: 29
Sustained endosomal release of a neurokinin-1 receptor antagonist from nanostars provides long-lasting relief of chronic pain
Rocco Latorre, Paulina D. Ramírez-García, Alan Hégron, et al.
Biomaterials (2022) Vol. 285, pp. 121536-121536
Open Access | Times Cited: 26
Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance
Marilina García-Aranda, Teresa Téllez, Lauraine McKenna, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2255-2255
Open Access | Times Cited: 24
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses
Kavita Vats, Oleg Kruglov, Bikram Sahoo, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 9, pp. 1141-1154
Open Access | Times Cited: 24
The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells
Maryam Momen Razmgah, Atefeh Ghahremanloo, Hossein Javid, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 10, pp. 9307-9314
Closed Access | Times Cited: 22
Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation
Xueyan Cao, Yang Yang, Wei Zhou, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Prospective clinical evidence from over 1,000 pan-cancer patients: a complement to fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting
Lijuan He, Jize Wang, Weigao Pu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
A Novel Mechanism of Endoplasmic Reticulum Stress‐ and c‐Myc‐Degradation‐Mediated Therapeutic Benefits of Antineurokinin‐1 Receptor Drugs in Colorectal Cancer
Yue Shi, Xi Wang, Yueming Meng, et al.
Advanced Science (2021) Vol. 8, Iss. 21
Open Access | Times Cited: 32
Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer
Mahtab Mozafari, Safieh Ebrahimi, Reza Assaran Darban, et al.
Molecular Biology Reports (2021) Vol. 49, Iss. 2, pp. 1067-1076
Closed Access | Times Cited: 30
Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Prema Robinson, Rafael Coveñas, Miguel Muñoz
Current Medicinal Chemistry (2022) Vol. 30, Iss. 16, pp. 1798-1812
Closed Access | Times Cited: 21
Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer
Rafael Coveñas, Miguel Muñoz
Cancers (2022) Vol. 14, Iss. 14, pp. 3539-3539
Open Access | Times Cited: 19
The in vitro anti‐cancer synergy of neurokinin‐1 receptor antagonist, aprepitant, and 5‐aminolevulinic acid in glioblastoma
Safieh Ebrahimi, Farshad Mirzavi, Seyed Isaac Hashemy, et al.
BioFactors (2023) Vol. 49, Iss. 4, pp. 900-911
Open Access | Times Cited: 12
An updated review on 1,2,3-/1,2,4-triazoles: synthesis and diverse range of biological potential
Anirudh Pratap Singh Raman, M. Aslam, Amardeep Awasthi, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 4
Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma
Miguel Muñoz, Marisa Rosso
Cancers (2025) Vol. 17, Iss. 3, pp. 520-520
Open Access
The neuroscience of cancer: Focus on neuropeptidergic systems
Zi-Kai Dong, Yongfei Wang, Weilin Jin
Acta Pharmaceutica Sinica B (2025)
Open Access
Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients
Marziyeh Ghorbani, Soha Namazi, Mehdi Dehghani, et al.
Breast Cancer Research and Treatment (2025)
Closed Access
The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis
Mohammed Ali Alsaeed, Safieh Ebrahimi, Abbas Alalikhan, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 18
The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders
Safieh Ebrahimi, Abbas Alalikhan, Seyed Hamid Aghaee‐Bakhtiari, et al.
Life Sciences (2022) Vol. 296, pp. 120448-120448
Closed Access | Times Cited: 16
The Synergistic Effects of Curcumin and Chemotherapeutic Drugs in Inhibiting Metastatic, Invasive and Proliferative Pathways
Maria Younes, Rita Mardirossian, Liza Rizk, et al.
Plants (2022) Vol. 11, Iss. 16, pp. 2137-2137
Open Access | Times Cited: 16
Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients
Prema Robinson, Marisa Rosso, Miguel Muñoz
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2135-2135
Open Access | Times Cited: 9
The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study
Abbas Alalikhan, Safieh Ebrahimi, Ali Aliee, et al.
Medical Oncology (2024) Vol. 41, Iss. 3
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top